Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Stephen Gracon, D.V.M., Joins the NanoBio Team as Vice President of Regulatory Affairs

Abstract:
NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the addition of Stephen Gracon, D.V.M., as Vice President of Regulatory Affairs.

Stephen Gracon, D.V.M., Joins the NanoBio Team as Vice President of Regulatory Affairs

ANN ARBOR, MI | Posted on January 16th, 2008

In his new role, Dr. Gracon will lead the regulatory and quality assurance activities for the company's rich pipeline of anti-infective products and mucosal vaccines.

Dr. Gracon brings 30 years of experience to NanoBio in diverse areas within the pharmaceutical industry, including pathology and experimental toxicology, clinical research, and regulatory affairs within the United States and internationally. Dr. Gracon served in various clinical, research and regulatory positions at Parke-Davis, Pfizer, Amgen and Baxter prior to joining NanoBio. He has a unique combination of experience with both small and large molecules in a broad range of indications, as well as with seasonal and pandemic vaccines and plasma-derived products.

"NanoBio's platform is very unique and has tremendous potential far beyond the current indications under investigation," said Dr. Gracon. "My role is to develop and execute strategies with the NanoBio team to navigate and expedite the FDA approval process for the numerous topical agents and vaccines that can be developed from our proprietary nanotechnology platform."

"We are very fortunate to have Dr. Gracon's extensive regulatory experience as we prepare for multiple regulatory submissions," added James Baker Jr., M.D., founder and CSO of NanoBio Corporation. "His specialized knowledge of regulatory protocol for both therapeutics and vaccines will be critical to moving NanoBio's products to FDA approval."

####

About NanoBio Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
NanoBio® Corporation

2311 Green Road, Suite A
Ann Arbor, Michigan 48105
Telephone:734.302.4000
Fax:734.302.9150
V.P. Business Development:
John Coffey (Ext. 107)

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Announcements

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016

Appointments/Promotions/New hires/Resignations/Deaths

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

Park Systems Global Expansion in AFM Market Includes Appointment of New Executives April 23rd, 2016

GLOBALFOUNDRIES Adds Alain Mutricy as Head of Product Management Group March 3rd, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project